Moderna, Inc. - Common Stock (MRNA)

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the Cambridge-based biotechnology pioneer is mid-pivot into what CEO Stéphane Bancel describes as "Moderna 2.0." The company that once boasted a market capitalization exceeding $150 billion during the [...]

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

The American corporate engine has proven far more durable than even the most optimistic analysts predicted just a year ago. As of March 27, 2026, final results for the fourth quarter of 2025 have confirmed a blended earnings growth rate of 14.2% for the S&P 500. This milestone

They could make important breakthroughs in their target markets.

As of March 25, 2026, the global economic landscape has shifted from the volatility of previous years into a phase of "tenuous resilience." Fueled by a significant rebound in international trade and a surge in high-tech manufacturing, U.S. equity markets have shattered previous records in the opening quarter of

As of March 25, 2026, the S&P 500 stands at a critical crossroads. After a historic three-year run that saw the benchmark index post double-digit gains in 2023, 2024, and a robust 17.9% in 2025, investors are left wondering if the "AI Supercycle" has finally run out of

Moderna's full pipeline may fuel long-term growth.

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

They aren't just "pandemic stocks."

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper echelons of the S&P 500 performance charts. This rally marks a definitive end to the "post-pandemic

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the beginning of a high-stakes pivot toward oncology. The German biotech pioneer recorded a net loss of €1.1 billion

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding...

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a household name during the COVID-19 pandemic, this latest rally signals a critical maturation point. Investors are no longer valuing Moderna solely on its [...]

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant Sciences and Arbutus Biopharma (NASDAQ:ABUS). Announced on March 3, 2026, the deal concludes one of the most contentious patent